TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alterity Therapeutics ( (ATHE) ) just unveiled an update.
On September 4, 2025, Alterity Therapeutics Limited announced a trading halt on its securities, pending a significant announcement related to a capital raising. The halt is expected to last until the earlier of the announcement release or the commencement of normal trading on September 8, 2025. This move signals a potential strategic financial maneuver that could impact the company’s market position and stakeholder interests.
The most recent analyst rating on (ATHE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
The overall stock score for Alterity Therapeutics is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows posing significant risks. However, technical analysis indicates strong upward momentum, which partially offsets the negative financial outlook. The poor valuation due to a negative P/E ratio further depresses the score. Without earnings call insights or new corporate events, the score reflects the current financial and technical conditions.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise in the biotechnology industry, focusing on innovative therapies for neurodegenerative diseases. The company is listed on the Australian Securities Exchange (ASX) and the NASDAQ, indicating a focus on both domestic and international markets.
Average Trading Volume: 82,191
Technical Sentiment Signal: Buy
Current Market Cap: $78.27M
See more insights into ATHE stock on TipRanks’ Stock Analysis page.